Company: ZVRA
Filing Date: 2025-05-08
Form Type: DEFA14A
Source: 0001193125-25-115961
Chunk: 11

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-08
Form: DEFA14A
Chunk 11
---
qualified director nominees and no stated business strategy A proven team with a clear strategy, strong momentum, and a track record of increasing stockholder value OR

Stockholders Have Two Options: Risk Disruption by a Single Stockholder with No Stated Strategy or A Proven Team With a Clear Strategy and Strong Momentum If Mangless’ two nominees are elected this year, his nominees would have five of eight Board seats in total, raising questions over control and the amount of undue influence one stockholder should have on the Board Lacks strategies, plans, or new ideas to improve Zevra’s business Mangless’ nominees massively destroyed stockholder value in previous roles Mangless’ nominees either lack independence, business experience, and/or necessary expertise to oversee a highly specialized rare disease company like Zevra Achieved key milestones in the last two years Delivered superior returns for stockholders Continued execution of strategy, focused on creating long-term value Highly engaged and refreshed Board Directors are exceptionally qualified, independent, and have track records of value creation

Stockholders Have Two Options: - 97.4% TSR During Dr. Mickle’s Tenure as CEO of Zevra2 62.6% TSR During Neil McFarlane’s Tenure1 Risk Disruption by a Single Stockholder with No Stated Strategy or A Proven Team With a Clear Strategy and Strong Momentum Source: Factset Research Systems, Inc. 10/9/23 to 5/7/25 Source: Factset Research Systems, Inc. 4/17/15 to 1/9/23

Launched two rare disease therapies, MIPLYFFA™ and OLPRUVA®, refreshed the Board and expanded purpose-build management team, and rapidly built Zevra’s robust internal commercial capabilities Completed a comprehensive review of our development pipeline to facilitate investment in the most promising, highest return opportunities Launched Phase 3 DiSCOVER trial and actively working to maximize the value of KP1077 Secured a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval of MIPLYFFA and sold it for $150 million in April 2025 Added significant expertise to support the Company’s growth and help us continue to drive operational excellence across our commercial and pre-commercial programs Strengthened Zevra’s balance sheet, providing the Company with ample resources and financial flexibility to execute on our strategy independent of the capital markets Wendy L. Dixon, Ph.D. Director since April 2023 and member of Audit Committee Tamara A. Favorito Board Chair since May